Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald increased their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Trading Up 1.3 %

Shares of NASDAQ:VNDA opened at $5.29 on Thursday. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The company’s 50 day moving average is $5.60 and its two-hundred day moving average is $5.05. The company has a market cap of $308.35 million, a PE ratio of -66.13 and a beta of 0.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million during the quarter. As a group, equities research analysts expect that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP increased its holdings in shares of Vanda Pharmaceuticals by 39.8% in the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Sei Investments Co. raised its holdings in Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after acquiring an additional 147,066 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Vanda Pharmaceuticals during the first quarter worth about $1,158,000. Acadian Asset Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 4.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after acquiring an additional 107,203 shares during the period. Finally, Raymond James & Associates purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth approximately $42,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.